Groupe Francais De Pneumo-cancerologie

This study tests whether adding a local treatment (like radiation or surgery) to the targeted therapy brigatinib can better control advanced ALK-positive lung cancer. About 45 adults whose cancer has shrunk or stabilized on brigatinib alone will receive the extra treatment. The g…

This study collects and analyzes tumor tissue and blood samples from 100 people with advanced ALK-positive non-small cell lung cancer. The goal is to learn more about the biological features of the cancer and how it responds to newer targeted therapies. Participants are already p…

This study looks at why the drug amivantamab stops working in people with a specific type of advanced lung cancer (NSCLC with EGFR exon 20 insertion). Researchers will collect blood and tumor samples from 30 patients when their disease gets worse. The goal is to find genetic chan…